Top 20 Immunology Companies of 2026 

Shots:  AbbVie led the global immunology market with $30.4B in immunology revenue in 2025, followed by Sanofi ($19.08B) and Johnson & Johnson ($15.72B). Continued demand for biologics and targeted therapies across autoimmune and inflammatory diseases supported strong commercial performance among leading companies.   The global immunology market, valued at $108.4B in 2024, is projected to reach $286.4B by 2034, expanding at a CAGR of 10.2% from 2025 to 2034. Growth is driven by an ageing population, the rising prevalence of immune-mediated disorders, increasing biologics adoption, and continued innovation in IL-17, IL-23, JAK, TYK2, and anti-IgE therapies.  The report is based on immunology segment revenues reported during fiscal year 2025, encompassing both established and next-generation therapies to deliver a comprehensive ranking of the world’s leading immunology companies. It highlights the strong commercial momentum of leading brands, including Skyrizi, Rinvoq, Dupixent, Tremfya, Bimzelx, Vyvgart, Cosentyx, Sotyktu, Saphnelo, and Ebglyss, while showcasing the innovative therapies reshaping the immunology landscape across autoimmune, inflammatory, and rare immune-mediated diseases.  20. Incyte  Immunology Segment Revenue: $0.82B   Founded Year: 2002   Market Cap: $23.3B   Total Employees: 2,800  Headquarters: Delaware, United States  Stock Exchange: NASDAQ   Incyte researches, develops, and commercializes innovative medicines focused on oncology, immunology, and inflammation, with an emphasis on targeted therapies for immune-mediated diseases  Olumiant and Opzelura are Incyte’s leading immunology products. In 2025, the company’s immunology revenue increased to $0.82B from $0.64B in 2024, recording a 28.1% increase over the previous year, primarily driven by strong demand and higher refill rates for Opzelura in the US across atopic dermatitis and vitiligo  In June 2026, Incyte reported positive 24-week P-III (TRuE-AD4) study results for Opzelura (ruxolitinib) cream in patients with moderate atopic dermatitis, further supporting the expansion of its immunology portfolio  19. Organon & Co. (Sun Pharma)  Immunology Segment Revenue: $0.95B   Founded Year: 2020   Market Cap: N/A   Total Employees: 4,000   Headquarters: New Jersey, United States  Stock Exchange: NYSE   Organon develops, manufactures, and commercializes medicines and biosimilars across women’s health, biosimilars, and established brands, including therapies for immunology and inflammatory diseases. In April 2026, Sun Pharma entered into a definitive agreement to acquire Organon in an all-cash transaction valued at approximately $11.75B  Arcoxia, Hadlima, Brenzys, Vtama and Renflexis are Organon’s leading immunology products. In 2025, the company’s immunology revenue increased to $0.95B from $0.77B in 2024, reflecting a 23.37% increase over the previous year, primarily driven by higher sales across its immunology portfolio  In June 2026, Organon and Samsung Bioepis expanded their commercialization agreement for Pyzchiva (ustekinumab), a biosimilar referencing Stelara (ustekinumab), to include the Canadian market  18. Astellas  Immunology Segment Revenue: $1.28B   Founded Year: 1923   Market Cap:  $23.97B   Total Employees: 14,099   Headquarters: Tokyo, Japan  Stock Exchange: TYO   Astellas researches, develops, manufactures, and commercializes innovative medicines across oncology, urology, ophthalmology, immunology, and other specialty therapeutic areas  Prograf is Astellas’ leading immunology product, used to prevent organ transplant rejection by suppressing the immune system. In 2025, the company’s immunology revenue declined to approximately $1.28B from $1.31B in 2024, reflecting a 2.3% decrease from the previous year, primarily due to lower sales of Prograf  In May 2026, Astellas unveiled its five-year strategic plan, shifting its R&D focus toward targeted immuno-oncology and advancing ASP2138, a bispecific T-cell engager targeting CLDN18.2 for the treatment of gastric and pancreatic cancers  17. Merck KGaA  Immunology Segment Revenue: $1.95B   Founded Year: 1668  Market Cap:  $67.74B   Total Employees: 62,500  Headquarters: Darmstadt, Germany  Stock Exchange: ETR  Merck KGaA researches, develops, manufactures, and commercializes innovative medicines across healthcare, life science, and electronics, with a focus on immunology, oncology, neurology, fertility, and endocrinology  Mavenclad and Rebif are Merck KGaA’s leading immunology products. In 2025, the company’s immunology revenue increased to $1.95B from $1.75B in 2024, reflecting an 11.4% increase over the previous year, primarily driven by higher sales of Mavenclad   In July 2026, the US FDA granted Breakthrough Therapy Designation to enpatoran for the treatment of lupus patients with active cutaneous manifestations  16. GSK  Immunology Segment Revenue: $2.39B   Founded Year: 2000  Market Cap:  $104.02B   Total Employees: 66,800   Headquarters: London, United Kingdom  Stock Exchange: LON  GSK researches, develops, manufactures, and commercializes innovative medicines and vaccines across immunology, infectious diseases, respiratory diseases, oncology, HIV, and other therapeutic areas  Benlysta is GSK’s leading immunology product. In 2025, the company’s immunology revenue increased to $2.39B from $1.87B in 2024, reflecting an 27.8% increase from the previous year, driven by strong demand, higher treatment volumes, and increased biologic penetration across multiple markets  In February 2026, GSK agreed to acquire 35Pharma for up to $950M, strengthening its immunology and respiratory pipeline with the addition of GSK’227, an investigational biologic targeting inflammatory diseases  15. Pfizer  Immunology Segment Revenue: $2.64B   Founded Year: 1849  Market Cap:  $143.28B   Total Employees: 75,000   Headquarters: New York, United States  Stock Exchange: NYSE   Pfizer researches, develops, manufactures, and commercializes innovative medicines and vaccines across immunology, oncology, internal medicine, inflammation, rare diseases, and infectious diseases Xeljanz, Enbrel, Inflectra/Remsima, Cibinqo, and Litfulo are Pfizer’s leading immunology products. In 2025, the company’s immunology revenue was $2.64B, compared with $2.65B in 2024, remaining essentially flat with a marginal 0.4% decline, primarily due to lower sales of Xeljanz and Enbrel In January 2026, Pfizer entered into a $530M agreement with Novavax to utilize its adjuvant technology in product development, supporting the advancement of next-generation vaccine and immunology programs 14. Eli Lilly  Immunology Segment Revenue: $2.96B   Founded Year: 1876   Market Cap:  $1.10T Total Employees: 50,000   Headquarters:  Indianapolis, United States  Stock Exchange: NYSE   Eli Lilly researches, develops, manufactures, and commercializes innovative medicines across immunology, diabetes, obesity, oncology, neuroscience, and other therapeutic areas Taltz, Olumiant, and other immunology products comprise Eli Lilly’s immunology portfolio. In 2025, the company’s immunology revenue increased to $2.96B from $2.45B in 2024, recording a 20.8% increase over the previous year, primarily driven by higher sales across its immunology portfolio In July 2026, the USFDA approved Ebglyss (lebrikizumab-lbkz) as an every-8-week (Q8W) maintenance treatment for adults and adolescents with moderate-to-severe atopic dermatitis  13. Argenx N.V.  Immunology Segment Revenue: $4.15B   Founded Year: 2008   Market Cap:  $52.73B   Total Employees: 1,900  Headquarters:  Amsterdam, Netherlands   Stock Exchange: EBR  Argenx N.V. researches, develops, and commercializes innovative antibody-based therapies focused on treating severe autoimmune diseases and rare immune-mediated disorders Vyvgart is Argenx’s flagship immunology product. In 2025, the company’s immunology revenue increased to $4.15B from $2.18B in 2024, representing a remarkable 90.4% increase from 2024, driven by strong global commercialization of Vyvgart and continued regulatory approvals across multiple markets  In June 2026, the USFDA approved Vyvgart and Vyvgart Hytrulo for adults with generalized myasthenia gravis (gMG), further expanding Argenx’s immunology portfolio and patient access  12. Bristol-Myers Squibb  Immunology Segment Revenue: $4.57B   Founded Year: 1887   Market Cap:  $123.57B   Total Employees: 32,500   Headquarters: New Jersey, United States   Stock Exchange: NYSE   Bristol-Myers Squibb researches, develops, manufactures, and commercializes innovative medicines across oncology, hematology, immunology, cardiovascular, neuroscience, and other therapeutic areas Orencia, Sotyktu, and Zeposia are Bristol-Myers Squibb’s leading immunology products. In 2025, the company’s immunology revenue increased to $4.57B from US$4.49B in 2024, reflecting a 1.8% increase over the previous year, driven by overall growth in sales across its immunology portfolio In June 2026, Bristol-Myers Squibb entered a potential $15.2B collaboration with Hengrui Pharma to advance 13 early-stage programs across oncology, hematology, and immunology, further strengthening its immunology pipeline 11. Biogen  Immunology Segment Revenue: $4.73B   Founded Year: 1978   Market Cap:  $30.84B Total Employees: 7,500   Headquarters: Massachusetts, United States   Stock Exchange: NASDAQ   Biogen researches, develops, manufactures, and commercializes innovative medicines across neurology, immunology, rare diseases, and specialized therapeutics Tysabri, Flixabi (biosimilar), Tecfidera, Vumerity, and Avonex are Biogen’s leading immunology products. In 2025, the company’s immunology revenue declined to $4.73B from $5.03B in 2024, reflecting a 6.0% decrease from the previous year, primarily due to lower Tysabri sales amid increasing competition, including the impact of biosimilar entrants in Europe   In June 2026, Biogen agreed to acquire RayThera to expand its immunology pipeline, adding novel therapeutic candidates aimed at treating immune-mediated diseases and strengthening its long-term inflammation portfolio 10. UCB  Immunology Segment Revenue: $5.56B   Founded Year: 1928   Market Cap:  $52.85B   Total Employees: 9,800   Headquarters: Brussels, Belgium   Stock Exchange: EBR   UCB researches, develops, manufactures, and commercializes innovative medicines across immunology, neurology, and rare diseases, with a strong focus on severe immune-mediated disorders Cimzia, Bimzelx, Rystiggo and Zilbrysq are UCB’s leading immunology products. In 2025, the company’s immunology revenue increased to $5.56B from $3.03B in 2024, surging 83.49% compared to the previous year, primarily driven by the successful global launches of Bimzelx   In May 2026, UCB agreed to acquire Candid Therapeutics for up to $2.2B, expanding its immunology pipeline with next-generation T-cell engager therapies for autoimmune diseases  09. Regeneron Pharmaceuticals  Immunology Segment Revenue: $5.88B   Founded Year: 1988   Market Cap:  $71.18B   Total Employees: 15,300   Headquarters: New York, United States   Stock Exchange: NASDAQ  Regeneron Pharmaceuticals discovers, develops, manufactures, and commercializes innovative medicines across immunology, oncology, ophthalmology, cardiovascular, infectious diseases, and rare diseases Dupixent and Kevzara are Regeneron’s leading immunology products. In 2025, the company’s immunology revenue increased to $5.88B from $4.53B in 2024, representing a 29.8% year-over-year increase, primarily driven by higher sales of its immunology portfolio In June 2026, Regeneron highlighted the expansion of its immunology portfolio and pipeline, showcasing positive clinical progress across multiple investigational therapies for allergic, inflammatory, and autoimmune diseases  08. Takeda  Immunology Segment Revenue: $6.81B   Founded Year: 1781   Market Cap:  $54.11B   Total Employees: 47,029  Headquarters: Tokyo, Japan   Stock Exchange: TYO   Takeda researches, develops, manufactures, and commercializes innovative medicines across gastroenterology and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines Entyvio is Takeda’s key immunology product. In 2025, the company’s immunology revenue increased to $6.81B from $6.43B in 2024, reflecting a 5.9% increase over the previous year, driven by overall growth in sales across its plasma-derived therapies portfolio In July 2026, Takeda reported positive Phase III LATITUDE-ATLAS study results for zasocitinib, demonstrating significant efficacy in adults with moderate-to-severe plaque psoriasis  07. Roche  Immunology Segment Revenue: $7.01B   Founded Year: 1896   Market Cap:  $337.02B   Total Employees:  1,12,800  Headquarters:  Basel, Switzerland   Stock Exchange: SWX   Roche researches, develops, manufactures, and commercializes innovative pharmaceuticals and diagnostics across oncology, immunology, neuroscience, ophthalmology, and other therapeutic areas Actemra/RoActemra, Xolair, and MabThera/Rituxan are Roche’s leading immunology products. In 2025, the company’s immunology revenue increased to $7.01B from $5.66B in 2024, representing a 23.9% year-over-year increase, driven by strong growth of Xolair in food allergy and the USFDA approvals of Gazyva/Gazyvaro for lupus nephritis and systemic lupus erythematosus In July 2026, Roche entered into a collaboration and licensing agreement worth up to US$3B with Nurix Therapeutics to develop bexobrutideg, an oral BTK degrader, further strengthening its immunology pipeline for autoimmune diseases  06. AstraZeneca  Immunology Segment Revenue: $7.24B   Founded Year: 1999   Market Cap:  $260.33B   Total Employees: 96,100   Headquarters: Cambridge, United Kingdom   Stock Exchange: LON   AstraZeneca researches, develops, manufactures, and commercializes innovative medicines across oncology, biopharmaceuticals, and rare diseases, with a growing focus on immunology and inflammation Saphnelo, Soliris, and Ultomiris are AstraZeneca’s leading immunology products. In 2025, the company’s immunology revenue increased to $7.24B from $6.98B in 2024, representing a 3.7% year-over-year increase, primarily driven by higher sales of Ultomiris In June 2026, AstraZeneca announced positive Phase III MIRANDA study results for tozorakimab, an anti-IL-33 monoclonal antibody, marking the third successful Phase III study in COPD and further strengthening its immunology and respiratory pipeline  05. Amgen  Immunology Segment Revenue: $7.3B   Founded Year: 1980   Market Cap:  $200.54B   Total Employees: 31,500   Headquarters: California, United States   Stock Exchange: NASDAQ  Amgen discovers, develops, manufactures, and commercializes innovative biologic medicines across inflammation, oncology, cardiovascular, bone health, nephrology, and rare diseases  Enbrel, Otezla, Tezspire, and Krystexxa are Amgen’s key immunology products. In 2025, the company’s immunology revenue declined to $7.30B from $7.59B in 2024, down 3.8% from 2024, primarily due to lower sales of Enbrel  In June 2026, Amgen reported positive Phase III study results for Tepezza (teprotumumab-trbw) in patients with active thyroid eye disease, further strengthening its immunology portfolio  04. Novartis  Immunology Segment Revenue: $10.29B   Founded Year: 1996   Market Cap:  $312.33B   Total Employees: 75,300   Headquarters: Basel, Switzerland   Stock Exchange: SWX   Novartis researches, develops, manufactures, and commercializes innovative medicines across immunology, cardiovascular, renal, metabolic, neuroscience, oncology, and other therapeutic areas Cosentyx, Xolair, Rhapsido and Ilaris are Novartis’ key immunology products. In 2025, the company’s immunology revenue increased to $10.29B from $9.29B in 2024, marking a 10.8% growth compared to 2024, primarily driven by strong sales growth of Cosentyx and Ilaris In March 2026, Novartis agreed to acquire Excellergy for up to $2B, adding the Phase I anti-IgE candidate Exl-111 to strengthen its allergy and immunology pipeline for IgE-driven diseases 03. Johnson & Johnson  Immunology Segment Revenue: $15.72B   Founded Year: 1886   Market Cap:  $601.73B   Total Employees: 138,200   Headquarters: New Jersey, United States   Stock Exchange: NYSE   Johnson & Johnson researches, develops, manufactures, and commercializes innovative medicines across immunology, oncology, neuroscience, cardiovascular, pulmonary hypertension, and other therapeutic areas Remicade, Simponi/Simponi Aria, Stelara, and Tremfya are Johnson & Johnson’s key immunology products. In 2025, the company’s immunology revenue declined to $15.72B from $17.82B in 2024, reflecting an 11.8% decline from the previous year, primarily due to lower Stelara (ustekinumab) sales following biosimilar competition and the impact of the Medicare Part D redesign In June 2026, the USFDA approved a label expansion for Tremfya (guselkumab) to help inhibit the progression of structural joint damage in adults with active psoriatic arthritis  02. Sanofi  Immunology Segment Revenue: $19.08B   Founded Year: 1973   Market Cap:  $107.01B   Total Employees: 74,800  Headquarters: Paris, France   Stock Exchange: NASDAQ  Sanofi researches, develops, manufactures, and commercializes innovative medicines and vaccines across immunology, rare diseases, oncology, neurology, and other therapeutic areas Dupixent and Kevzara are Sanofi’s leading immunology products. In 2025, the company’s immunology revenue increased to $19.08B from $12.32B in 2024, representing a 54.9% year-over-year increase, primarily driven by higher sales of Dupixent and Kevzara In June 2026, Wayrilz (rilzabrutinib) received approval in Japan for the treatment of persistent or chronic immune thrombocytopenia (ITP), expanding Sanofi’s immunology portfolio  01. AbbVie   Immunology Segment Revenue: $30.4B   Founded Year: 2013   Market Cap: $449.45B   Total Employees: 57,000  Headquarters: Illinois, United States   Stock Exchange: NYSE   AbbVie discovers, develops, manufactures, and commercializes innovative medicines across immunology, oncology, neuroscience, eye care, aesthetics, and other chronic and complex diseases Humira, Skyrizi, and Rinvoq are AbbVie’s leading immunology products. In 2025, the company’s immunology revenue increased to $30.4B from $26.68B in 2024, representing a 13.9% increase from 2024, primarily driven by the continued strong growth of Skyrizi and Rinvoq  In June 2026, the US FDA approved Skyrizi (risankizumab) for pediatric patients aged six years and older with moderate-to-severe plaque psoriasis and active psoriatic arthritis, expanding AbbVie’s immunology portfolio into pediatric psoriatic disease  Criteria:   The report is based on immunology segment revenues reported during fiscal year 2025, encompassing both established and next-generation therapies to deliver a comprehensive ranking of the world’s leading immunology companies  For companies with non-December fiscal year endings, revenue has been calculated for the January–December 2025 period using quarterly and annual financial filings. Where vaccine-specific sales were not disclosed, estimates were derived from publicly available company reports and credible secondary sources   Market capitalisation is considered as of 17 July 2026. Revenues reported in different currencies have been converted into US dollars using exchange rates as of 31 December 2025 to ensure consistency across all rankings Source:   Company Websites      Press Releases        Annual Reports       Quarterly Reports     Google Finance         OANDA        Related Post: Top 20 Immunology Companies of 2025  The post Top 20 Immunology Companies of 2026  appeared first on PharmaShots.